# Impetigo

Manage typical impetigo clinically with lesion-directed therapy, reserving culture for atypical, recurrent, or outbreak-associated disease. Use topical treatment for limited disease, oral therapy for numerous lesions or transmission control, and identify ecthyma because it requires systemic treatment.

**Clinical question:** How should physicians diagnose, treat, culture, and limit transmission of bullous, nonbullous, and ecthymatous impetigo?

Updated: 2026-09-15T23:26:46.337489+00:00

## What matters in practice
- Typical impetigo is a clinical diagnosis; Gram stain and culture of lesion exudate are recommended when organism identification will change management, although empiric treatment without testing is reasonable in typical presentations. [20][22]
- Use topical mupirocin or retapamulin twice daily for 5 days for limited bullous or nonbullous impetigo. [22]
- Choose oral therapy for numerous lesions, outbreaks involving several people, or ecthyma; ecthyma should not be managed with topical treatment alone. [22]
- Oral therapy should cover both Staphylococcus aureus and group A streptococci because examination cannot reliably distinguish staphylococcal from streptococcal nonbullous impetigo. [20]
- Reduce household and institutional spread by covering lesions, daily laundering of used linens and towels without sharing, and hand hygiene; return to school or work is permitted at least 12 hours after antibiotics are started if lesions are covered. [20]

## Separate limited impetigo from ecthyma, extensive disease, and alternative diagnoses

The lesion pattern and burden determine route of therapy and whether testing is needed.

Treat a typical superficial, crusted eruption as impetigo on clinical grounds. Nonbullous impetigo commonly follows minor cutaneous trauma and affects the face or extremities; bullous impetigo produces flaccid bullae from toxin-producing S. aureus. [7][22] Do not use morphology to choose staphylococcal versus streptococcal coverage in nonbullous disease: physical examination cannot reliably make that distinction. [20]

Identify ecthyma as a management-changing branch. IDSA recommends an oral antimicrobial for ecthyma rather than topical therapy. [22] In a patient with a lesion that is not clinically typical, obtain a bacterial specimen and broaden the diagnostic assessment rather than repeatedly prescribing topical antibiotics.

Escalate from lesion-limited management to oral therapy when lesions are numerous or when several people are affected in an outbreak; this choice is intended to reduce transmission as well as treat the individual. [22] Bullous and nonbullous forms can otherwise be treated with either topical or oral antimicrobials. [8][22]
- Limited bullous or nonbullous lesions: topical treatment is an appropriate first route. [22]
- Numerous lesions or outbreak involving several people: select oral therapy. [22]
- Ecthyma: select oral therapy. [22]
- Intact suspected bulla when bacterial confirmation is needed: Gram stain of bulla fluid is a dermatologic use of Gram staining. [6]

*Route selection for impetigo is driven principally by extent, outbreak status, and ecthyma. [22]*

| Clinical branch | Next action | Reason management changes |
| --- | --- | --- |
| Typical limited bullous or nonbullous impetigo | Treat with topical mupirocin or retapamulin twice daily for 5 days. [22] | Topical therapy is an IDSA-recommended option for both morphologic forms. [22] |
| Numerous lesions | Use oral antimicrobial therapy. [22] | Oral therapy is recommended when lesion burden is high. [22] |
| Outbreak affecting several people | Use oral antimicrobial therapy and implement transmission precautions. [20][22] | Oral treatment is recommended to help decrease transmission. [22] |
| Ecthyma | Use an oral antimicrobial rather than topical therapy alone. [22] | Ecthyma requires systemic treatment. [22] |

## When to culture impetigo and how results change treatment

Testing is selective in routine presentations but useful when microbiology will alter treatment or public-health actions.

For impetigo or ecthyma, collect Gram stain and culture from lesion pus or exudate when pathogen identification is needed; IDSA recommends this approach to identify S. aureus and/or beta-hemolytic streptococci. [22] In a classic, limited presentation, empiric therapy without microbiology is reasonable. [22] CDC similarly notes that laboratory testing is not routinely performed, although culture or Gram stain of exudate or pus can identify the bacterial cause. [20]

Obtain culture before changing therapy in questionable lesions, recurrent disease, treatment nonresponse, or clustered cases in which susceptibility data may guide management and outbreak control. Culture is also useful in outbreaks of poststreptococcal glomerulonephritis to identify nephritogenic group A streptococcal strains. [4][16] A negative or nondiagnostic superficial sample should prompt reconsideration of the diagnosis rather than automatic escalation of antibiotic spectrum.

Interpret a culture in the clinical context: nonbullous impetigo may involve S. aureus, group A streptococci, or both, whereas bullous impetigo is associated with toxin-producing S. aureus. [4][22] Initial antimicrobial selection should cover both group A streptococci and S. aureus unless microbiology supports a narrower directed regimen. [20]
- Sample pus or exudate from an impetigo or ecthyma lesion for Gram stain and culture when a result will alter drug selection. [22]
- Routine culture is not required before treating a classic limited presentation. [20][22]
- For a suspected intact bullous lesion, consider Gram stain of bulla fluid rather than relying only on surface crust. [6]

*Microbiologic testing should be targeted to decisions that empiric topical management cannot resolve. [20][22]*

| Scenario | Test | Actionable interpretation |
| --- | --- | --- |
| Typical limited presentation | No routine laboratory test required. [20] | Begin clinically directed therapy; treatment without culture is reasonable. [22] |
| Questionable or atypical lesion | Culture and antimicrobial susceptibility testing of lesion material. [16] | Use microbiology to direct antibacterial therapy and reconsider the diagnosis if results do not support bacterial infection. |
| Suspected bullous impetigo with intact bulla | Gram stain of intact bulla fluid. [6] | Supports bacterial evaluation of a bullous eruption. [6] |
| Poststreptococcal glomerulonephritis outbreak | Culture to identify nephritogenic group A streptococcal strains. [4] | Supports outbreak investigation and targeted public-health response. [4] |

## Use topical therapy for limited disease and oral therapy when extent or transmission requires it

Select treatment route first; then ensure coverage for likely staphylococcal and streptococcal pathogens.

For limited bullous or nonbullous impetigo, prescribe mupirocin or retapamulin topically twice daily for 5 days. [22] Mupirocin ointment 2% has been evaluated in randomized impetigo trials. [1] Topical therapy limits systemic exposure and, for localized nonbullous disease, can be as effective as oral antibiotic treatment with minimal systemic adverse-effect risk from lower absorption. [23]

Use an oral antimicrobial when lesions are numerous or during outbreaks, and use oral therapy for ecthyma. [22] The oral regimen should be active against both S. aureus and group A streptococci. [20] In pediatric bullous impetigo, cephalexin or clindamycin is listed as recommended oral treatment. [24] Select an oral agent using patient allergy history, local susceptibility information, and culture results when obtained.

Do not extend or broaden treatment solely because lesions are initially widespread if culture and clinical response support the chosen regimen. Conversely, failure of a topical course should trigger reassessment of adherence, lesion diagnosis, bacterial culture, and the need for oral treatment rather than serial empiric topical substitutions. Resistance to mupirocin and fusidic acid has been reported and is a stewardship concern. [14][17]
- Topical route: mupirocin or retapamulin twice daily for 5 days for bullous or nonbullous impetigo. [22]
- Oral route: numerous lesions, an outbreak involving several individuals, or ecthyma. [22]
- Pediatric bullous disease: cephalexin or clindamycin is a recommended oral option. [24]
- Avoid choosing narrow streptococcal-only versus staphylococcal-only therapy based on the appearance of nonbullous lesions. [20]

### Stewardship considerations

Reserve systemic therapy for the route-selection indications rather than routinely treating all limited impetigo orally. Increasing resistance to common topical agents, including mupirocin and fusidic acid, makes culture-directed treatment particularly important after failure or in recurrent disease. [14][17]

*Treatment route and duration recommendations for impetigo. [22]*

| Patient or disease pattern | Preferred route | Regimen or selection rule |
| --- | --- | --- |
| Limited bullous or nonbullous impetigo | Topical | Mupirocin or retapamulin twice daily for 5 days. [22] |
| Numerous lesions | Oral | Use an oral antimicrobial that targets S. aureus and group A streptococci. [20][22] |
| Outbreak involving several people | Oral | Use oral therapy to help decrease transmission; cover lesions and use hygiene measures. [20][22] |
| Ecthyma | Oral | Treat with an oral antimicrobial. [22] |
| Child with bullous impetigo requiring oral therapy | Oral | Cephalexin or clindamycin is recommended. [24] |

## Limit autoinoculation, household spread, and school or workplace transmission

Transmission precautions should start with the first treatment dose, not after lesion resolution.

Cover all lesions to reduce spread to other people and to other body sites. [20] Reinforce hand hygiene and avoidance of lesion manipulation, because direct contact and excoriation facilitate transmission and autoinoculation. [4][20] This is especially important when lesions are on exposed areas, which commonly include the face and extremities. [20]

Instruct households to wash clothing, linens, and towels used by the affected person daily and not share them before washing. [20] After laundering, these items are safe for use by others. [20] In schools, daycare settings, and workplace clusters, pair these measures with oral treatment when an outbreak affects several people. [22]

Patients may return to school or work at least 12 hours after beginning antibiotic treatment if lesions are covered. [20] This timing rule applies alongside—not instead of—ongoing lesion coverage and hygiene.
- Cover lesions throughout the contagious period. [20]
- Wash used clothing, linens, and towels daily; do not share them before washing. [20]
- Permit school or work return at least 12 hours after antibiotic initiation when lesions are covered. [20]
- During multi-person outbreaks, use oral therapy and institute contact precautions to reduce transmission. [20][22]

*Practical transmission-control actions for impetigo. [20][22]*

| Setting | Action | Timing |
| --- | --- | --- |
| Patient | Cover lesions and perform hand hygiene. [20] | Start immediately and continue while lesions require coverage. |
| Household | Wash used clothing, linens, and towels daily; do not share them before washing. [20] | Daily during active infection. [20] |
| School or workplace | Return is permitted if lesions are covered after antibiotics have been started. [20] | At least 12 hours after initiating antibiotics. [20] |
| Outbreak affecting several people | Use oral therapy rather than topical treatment alone. [22] | At diagnosis of outbreak-associated cases. [22] |

## References
1. MUPIROCIN OINTMENT USP, 2% - DailyMed — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=da2f7d4e-82c6-4790-8eea-3a97e5b30734
2. Topical hydrogen peroxide versus fusidic acid for non-severe ... — www.thelancet.com — https://www.thelancet.com/journals/lanprc/article/PIIS3050-5143(25)00054-8/fulltext
3. Preventive efforts are required for impetigo - The Lancet Primary Care — www.thelancet.com — https://www.thelancet.com/journals/lanprc/article/PIIS3050-5143(25)00063-9/fulltext
4. Communicable Disease - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/nursing-and-health-professions/communicable-disease
5. Streptococcus antigen - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/streptococcus-antigen
6. Gram Staining - an overview | ScienceDirect Topics — sciencedirect.com — https://sciencedirect.com/topics/medicine-and-dentistry/gram-staining
7. Skin Microflora and Bacterial Infections of the Skin - ScienceDirect.com — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0022202X15529011
8. Practice Guidelines for the Diagnosis and Management of Skin and ... — academic.oup.com — https://academic.oup.com/cid/article/59/2/e10/2895845
9. Geriatric dermatoses: a clinical review of skin diseases in an aging ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/j.1365-4632.2011.05311.x
10. Topical Antibiotic Treatment of Impetigo with Tetracycline - 2005 — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/j.1346-8138.2005.tb00846.x
11. Impetigo: A need for new therapies in a world of increasing ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/jcpt.12639
12. Systematic review of the evidence for treatment and ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ftmi.14047
13. NICE on antimicrobial prescribing for impetigo - Chaplin - 2020 — wchh.onlinelibrary.wiley.com — https://wchh.onlinelibrary.wiley.com/doi/10.1002/psb.1850
14. Non-bullous Impetigo: Incidence, Prevalence, and Treatment in the Pediatric Primary Care Setting in Italy — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9008221
15. Intolerable Burden of Impetigo in Endemic Settings: A Review of the Current State of Play and Future Directions for Alternative Treatments — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7765423
16. Summary of Evidence - Topical Antibiotics for Impetigo: A Review of the Clinical Effectiveness and Guidelines - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK447577
17. Ozenoxacin 1% in Pediatric and Adult Patients with Impetigo: A Meta-Analysis of Randomized Trials — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11989652
18. Antibiotic stewardship in skin infections: a cross-sectional analysis of early-career GP’s management of impetigo — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6830714
19. Should all children, adolescents and adults presenting with laboratory-confirmed streptococcal skin infection be treated with antibiotics to prevent RF/RHD? If so, what is the best choice of antibiotics for treatment? - WHO guideline on the prevention and diagnosis of rheumatic fever and rheumatic heart disease - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK609706
20. Clinical Guidance for Group A Streptococcal Impetigo | Group A Strep | CDC — www.cdc.gov — https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/impetigo.html
21. Impetigo - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK430974
22. Skin and Soft Tissue Infections - IDSA — www.idsociety.org — https://www.idsociety.org/practice-guideline/skin-and-soft-tissue-infections
23. [PDF] Essential Medicines List Antibiotic Book — cdn.who.int — https://cdn.who.int/media/docs/default-source/essential-medicines/eml-antibiotic-book-draft.pdf
24. Skin and Soft-Tissue Infections - AAP Publications — publications.aap.org — https://publications.aap.org/books/chapter-pdf/1283614/aap_9781610020770-part01_section01_ch07.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.